MOG-IgG相关疾病保留激素的维持免疫治疗
结果显示维持免疫治疗可减少复发,IVIG的ARR最低,而传统MS疾病修饰药物均出现突破性复发。
要点
- 维持免疫治疗可降低MOGAD复发,IVIG的ARR最低(0)
- 传统MS疾病修饰药物在9例患者中均出现突破性复发
- 需前瞻性随机对照研究验证上述结论
核心结论
- 维持免疫治疗可减少MOGAD患者的中枢神经系统脱髓鞘复发,IVIG治疗的ARR最低。
- 传统MS疾病修饰药物似乎无效,9例患者均出现突破性复发。
研究设计与样本
- 患者初发年龄中位数29岁(范围3-61岁;33%<18岁),女性占59%。
主要发现
- 治疗前中位ARR为1.6。
- 维持治疗中复发比例:吗替麦考酚酯74%(14/19;ARR 0.67),利妥昔单抗61%(22/36;ARR 0.59),硫唑嘌呤59%(13/22;ARR 0.2),IVIG 20%(2/10;ARR 0)。
- 四种治疗总体中位ARR为0.3。
- 所有9例使用MS疾病修饰药物的患者均出现突破性复发(ARR 1.5)。
临床怎么用
- 对于MOGAD的长期维持治疗,可考虑IVIG以降低复发率。
- 应避免使用传统MS疾病修饰药物作为MOGAD的维持治疗。
局限性
- 回顾性研究设计可能引入选择偏倚。
- 结论需前瞻性随机对照研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) associated disorder (MOGAD) often manifests with recurrent CNS demyelinating attacks. The optimal treatment for reducing relapses is unknown. To help determine the efficacy of long-term immunotherapy in preventing relapse in patients with MOGAD, we conducted a multicenter retrospective study to determine the rate of relapses on various treatments. METHODS: We determined the frequency of relapses in patients receiving various forms of long-term immunotherapy for MOGAD. Inclusion criteria were history of ≥1 CNS demyelinating attacks, MOG-IgG seropositivity, and immunotherapy for ≥6 months. Patients were reviewed for CNS demyelinating attacks before and during long-term immunotherapy. RESULTS: Seventy patients were included. The median age at initial CNS demyelinating attack was 29 years (range 3-61 years; 33% <18 years), and 59% were female. The median annualized relapse rate (ARR) before treatment was 1.6. On maintenance immunotherapy, the proportion of patients with relapse was as follows: mycophenolate mofetil 74% (14 of 19; ARR 0.67), rituximab 61% (22 of 36; ARR 0.59), azathioprine 59% (13 of 22; ARR 0.2), and IV immunoglobulin (IVIG) 20% (2 of 10; ARR 0). The overall median ARR on these 4 treatments was 0.3. All 9 patients treated with multiple sclerosis (MS) disease-modifying agents had a breakthrough relapse on treatment (ARR 1.5). CONCLUSION: This large retrospective multicenter study of patients with MOGAD suggests that maintenance immunotherapy reduces recurrent CNS demyelinating attacks, with the lowest ARR being associated with maintenance IVIG therapy. Traditional MS disease-modifying agents appear to be ineffective. Prospective randomized controlled studies are required to validate these conclusions.
引用
- Chen JJ, Flanagan EP, Bhatti MT, et al. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology. 2020. PMID: 32554760. doi:10.1212/WNL.0000000000009758
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。